Besides its crucial role in the tumor development, the KRAS mutational status is also critical for the antiepidermal growth factor receptor (EGFR) therapy management in colorectal cancers, which has greatly improved the clinical outcome of the disease in the past decade [8–10]. This evidence concerns the gene EGFR and neoplasm.